Epidemiology of chronic myeloid leukaemia (CML)
M Rohrbacher, J Hasford - Best practice & research Clinical haematology, 2009 - Elsevier
Reliable epidemiological information on chronic myeloproliferative disorders (CMPDs),
notably Philadelphia (Ph)/BCR-ABL-positive chronic myeloid leukaemia (CML), is rare …
notably Philadelphia (Ph)/BCR-ABL-positive chronic myeloid leukaemia (CML), is rare …
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options
EJ Jabbour, JE Cortes, HM Kantarjian - Clinical Lymphoma Myeloma and …, 2013 - Elsevier
The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many
patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to …
patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to …
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications
E Jabbour, JE Cortes, HM Kantarjian - Cancer, 2008 - Wiley Online Library
The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …
First‐line treatment selection and early monitoring patterns in chronic phase‐chronic myeloid leukemia in routine clinical practice: SIMPLICITY
SL Goldberg, JE Cortes… - American journal of …, 2017 - Wiley Online Library
Achieving successful outcomes in chronic phase‐chronic myeloid leukemia (CP‐CML)
requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY …
requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY …
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
E Jabbour, JE Cortes, HM Kantarjian - Mayo Clinic Proceedings, 2009 - Elsevier
Treatment responses to imatinib vary among patients with chronic myeloid leukemia (CML),
and definitions of treatment failure and suboptimal response have been published. This …
and definitions of treatment failure and suboptimal response have been published. This …
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
BACKGROUND Tyrosine kinase inhibitors (TKIs) significantly improve survival in patients
with chronic myeloid leukemia in chronic phase (CML‐CP). Conditional probability provides …
with chronic myeloid leukemia in chronic phase (CML‐CP). Conditional probability provides …
Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era
DW Kim, SD Banavali, U Bunworasate, YT Goh… - Leukemia research, 2010 - Elsevier
Chronic myeloid leukemia (CML) management varies across Asia due to disparities in
affluence and healthcare provision. We surveyed CML management practice at 33 hospitals …
affluence and healthcare provision. We surveyed CML management practice at 33 hospitals …
Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET)
BACKGROUND: Treatment recommendations have been developed for management of
patients with chronic myeloid leukemia (CML). METHODS: A 30‐item multiple‐choice …
patients with chronic myeloid leukemia (CML). METHODS: A 30‐item multiple‐choice …
Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors
J Ou, JA Vergilio, A Bagg - American journal of hematology, 2008 - Wiley Online Library
The well‐established molecular pathogenesis of chronic myelogenous leukemia (CML) and
its consequences for laboratory testing and clinical management illustrate a classic …
its consequences for laboratory testing and clinical management illustrate a classic …
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors
M Bermejo, J Ambrosioni, G Bautista, N Climent… - Biochemical …, 2018 - Elsevier
Current antiretroviral treatment (ART) may control HIV-1 replication but it cannot cure the
infection due to the formation of a reservoir of latently infected cells. CD4+ T cell activation …
infection due to the formation of a reservoir of latently infected cells. CD4+ T cell activation …